1. Scrip
  2. >>Business

GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge

Company Expects To File In H1 2023

 
• By Andrew McConaghie

GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of  $1bn.

GSK scientists working in the lab
The novel antibiotic was discovered in GSK's labs, its development supported by funding from US government agency BARDA. • Source: GSK

GSK could soon have a novel antibiotic on the market, after the company revealed Phase III studies of the candidate gepotidacin were stopped early because of positive results.

Data from the EAGLE-2 and EAGLE-3 studies showed gepotidacin to be non-inferior to existing first-line treatment, nitrofurantoin, in treating uncomplicated urinary

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.